HTD1801 Shows Promising Histologic Improvement in Metabolic Dysfunction-Associated Steatohepatitis: Insights from Preclinical and Phase 2 Clinical Studies
Highlight
HTD1801 (berberine ursodeoxycholate) demonstrated significant histologic improvements in metabolic dysfunction-associated steatohepatitis (MASH) and associated fibrosis in both preclinical and clinical (Phase 2) studies. Its efficacy was reflected by biomarker improvements including liver fat content, fibrosis indices, and liver enzyme reductions. The findings suggest strong potential for HTD1801 as a therapeutic in MASH patients, particularly those with type 2 diabetes mellitus.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.